Publication date: September 2017
Source:European Journal of Cancer, Volume 83
Author(s): Nicolas Penel, Axel Le Cesne, Sylvie Bonvalot, Antoine Giraud, Emmanuelle Bompas, Maria Rios, Sébastien Salas, Nicolas Isambert, Pascaline Boudou-Rouquette, Charles Honore, Antoine Italiano, Isabelle Ray-Coquard, Sophie Piperno-Neumann, François Gouin, François Bertucci, Thomas Ryckewaert, Jean-Emmanuel Kurtz, Françoise Ducimetiere, Jean-Michel Coindre, Jean-Yves Blay
PurposeThe outcome of desmoid-type fibromatosis (DTF) is unpredictable. Currently, a wait-and-see approach tends to replace large en bloc resection as the first therapeutic approach. Nevertheless, there are no validated factors to guide the treatment choice.MethodWe conducted a prospective study of 771 confirmed cases of DTF. We analysed event-free survival (EFS) based on the occurrence of relapse after surgery, progressive disease during the wait-and-see approach, or change in therapeutic strategy. Identification of prognostic factors was performed using classical methods (log-rank test and Cox model).ResultsOverall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415). In univariate analysis, two prognostic factors significantly influenced the outcome: the nature of diagnostic sampling (p = 0.466) and primary location (p = 0.0001). The 2-year EFS was only 32% after open biopsy. The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).ConclusionThe location of DTF is a major prognostic factor for EFS. If these findings are confirmed by independent analysis, personalised management of DTF must consider this easily obtained parameter.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ubpJKG
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidiscip...
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Abstract Soil conditioners can be used to compensate for the insufficient soil nutrition and organic matter (OM) of arable soils. However, ...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pnBoX1 via IFTTT
-
Micro- and nanoparticles of NiSb2O6 were synthesized by the microwave-assisted colloidal method. Nickel nitrate, antimony chloride, ethylene...
-
Comparison of treatment outcomes between 10 and 20 EEG electrode location system-guided and neuronavigation-guided repetitive transcran...
-
An amplitude-modulated and frequency-modulated (AM-FM) radar with an active reflector to produce high-accuracy distance measurements is prop...
-
Abstract This article presents the development and experimental validation of a methodology to reduce the risk of thermal injury to the fa...
-
Publication date: 5 August 2017 Source: Gene, Volume 623 Author(s): Fei-Yan Xiao, Min Liu, Bi-Lian Chen, Shan Cao, Lan Fan, Zhao-Qian Liu...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου